Photo from Akash Maniam/LinkedIn
Oct 21, 2023, 19:19
Akash Maniam: Personally, the neoadjuvant IO data in early breast cancer is the most intriguing
Akash Maniam, a Medical Oncologist at Portsmouth Hospitals University NHS Trust, and the Clinical Director of Caribbean Cancer Research Institute, shared on LinkedIn:
“Stellar start to ESMO 2023. Personally, the neoadjuvant IO data in early breast cancer is the most intriguing. Increased pCR is fascinating, but does this translate into improved iDFS and OS? Is pCR as meaningful here as in HER2 positive and TNBC cohorts? Is the benefit only confined to PDL1-positive patients? How would adjuvant IO fare in an adjuvant CDK4/6i (and PARPi) world?
So much new data, so many more questions. Look forward to more!”
Source: Akash Maniam/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 13:46
Dec 21, 2024, 13:40
Dec 21, 2024, 13:33
Dec 21, 2024, 13:20
Dec 21, 2024, 13:12
Dec 21, 2024, 13:05